Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2025Expert Review of Pharmacoeconomics & Outcomes Research

Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting

View Full Paper
Ask AI
Bookmark
Share

Authors

PAPrachi AroraWMWojciech MichalakZZZhenxiang Zhao

Discussion

Loading...

Member takes

Overview

Observational analysis finds lower medical costs in overweight patients treated with semaglutide, indicating its value in healthcare resource utilization.

Key Points

  • Lower medical costs were associated with semaglutide treatment in patients with obesity, suggesting economic benefits.
  • Patients treated with semaglutide showed a significant reduction in healthcare resource utilization compared to those not treated.
  • The analysis focused on the real world setting, ensuring findings reflect typical medical practices and costs.
  • Implications of these findings highlight the potential for semaglutide to contribute to overall cost savings in obesity management.

Cite This Study

Arora et al. (2025) studied this question.

synapsesocial.com/papers/68e9435d2d5336d28fb2895ehttps://doi.org/10.1080/14737167.2025.2570688
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States2026 · 2 citations
  2. 2Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)2025 · 2 citations
  3. 3Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study2025 · 7 citations
  4. 4Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months)2025
  5. 5Semaglutide <scp>2.4 mg</scp> Cardiometabolic Long‐Term Effects in Patients With Obesity or Overweight in a Real‐World Setting: A Retrospective Cohort Study in the United States ( <scp>SMILE</scp> )2026